2 Artificial Intelligence (AI) in Healthcare Stocks to Buy and Hold for Great Long-Term Potential

Artificial intelligence (AI) has caught the eye of investors because of its potential to transform many industries, and the biggest impact could be in the area of healthcare. That’s because this technology could solve the No. 1 problem of drug development, the lengthy time it takes to bring a candidate from drawing board to commercialization. And it could result in better drugs and medical devices, leading to better patient outcomes.

All of this means companies leading the way may see their earnings explode higher over time. On top of this, the AI in healthcare market is expected to expand at a compound annual growth rate of 48% to reach $148 billion by 2029, according to Markets and Markets research, meaning we’re just at the start of this exciting story. Ready to get in on the most promising players early? Then consider these two AI in healthcare stocks to buy and hold for their great long-term potential.

Image source: Getty Images.

1. Moderna

Moderna (NASDAQ: MRNA) shares took off earlier in the pandemic as the company commercialized its coronavirus vaccine and generated billions of dollars in earnings. These days, vaccine demand is on the decline, and even though the product still is likely to generate recurrent revenue during fall vaccination seasons, it’s not set to return to the levels we’ve seen in the past. This has worried investors about the biotech’s future prospects.

But there’s reason to be optimistic about this innovative company. Moderna not only has many late-stage candidates in the pipeline, but it’s also making AI a priority. The company already has used the technology in the vaccine development process, speeding up certain key steps for researchers. And last year it announced a deal with International Business Machines to use the company’s technology to supercharge its research.

For example, it’s using IBM’s foundation model MolFormer to predict the properties of molecules, with the idea of developing better mRNA medicines more quickly. This is positive because it could result in products reaching the market faster, offering Moderna new sources…

..

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Social Media Auto Publish Powered By : XYZScripts.com